Recruiting

Tissue Collection for Cancer Research at NIH

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to collect and analyze tissue samples from individuals for cancer research to better understand the disease.

What is being collected

Data Collection

Who is being recruted

Blood Protein Disorders+16

+ Bone Marrow Diseases

+ Cardiovascular Diseases

Over 2 Months
+19 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Case-Only

Examining characteristics of individuals with a disease in order to identify genetic or environmental factors contributing to the condition.
Observational
Study Start: July 2006
See protocol details

Summary

Principal SponsorNational Cancer Institute (NCI)
Study ContactNancy A Moore, R.N.More contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: July 6, 2006

Actual date on which the first participant was enrolled.

This study focuses on collecting tissue samples from cancer patients to support research efforts at the National Cancer Institute (NCI). It involves both adult and pediatric patients who are receiving evaluation or treatment at the NIH Clinical Center and other participating sites. The goal is to gather tissue and fluid samples that can help in developing new cancer research models and understanding disease pathways. This research is important as it can lead to advancements in cancer treatment and better understanding of the disease, potentially benefiting future patients. Participants in this study will have samples collected from regular medical procedures they are already undergoing, or through additional minimally invasive methods like blood draws or biopsies. The samples collected may include blood, tumor tissue, and other bodily fluids. These samples will be de-identified, meaning they won’t be linked back to the individual, and used only for approved research studies. Risks associated with invasive procedures will be clearly communicated to participants, and proper consent will be obtained before any sample collection. The study uses different consent forms for adults and children to ensure understanding and agreement on how their samples will be used.

Official TitleTissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)
NCT00900198
Principal SponsorNational Cancer Institute (NCI)
Study ContactNancy A Moore, R.N.More contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

5000 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Case-only

These studies focus only on individuals who have a specific disease. Researchers examine patterns—often genetic or environmental—to uncover what might be linked to the condition.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 2 Months

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood Protein DisordersBone Marrow DiseasesCardiovascular DiseasesHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersImmune System DiseasesImmunoproliferative DisordersLymphatic DiseasesLymphomaLymphoproliferative DisordersMultiple MyelomaMyelodysplastic SyndromesNeoplasmsNeoplasms by Histologic TypeParaproteinemiasVascular DiseasesHemostatic DisordersNeoplasms, Plasma Cell

Criteria

8 inclusion criteria required to participate
Patients 18 years of age and older who are being evaluated and/or treated for cancer at the NIH Clinical Center or at participating sites: * Who have a newly diagnosed malignancy for which they have not yet received treatment, or * Who have a previously treated malignancy that is now recurrent or currently progressing on treatment indicated by: * radiographic evidence of tumor growth and/or new metastases, or * CBC w/differential and/or flow cytometry, or * documented evidence by the treating physician of signs/symptoms of clinical disease progression, or * Who are currently undergoing treatment and for whom disease response has not yet been assessed, ---In this circumstance, specimen collection should occur as distant in time from the most recent drug administration as possible such as after completion of a treatment cycle and immediately prior to initiation of the next cycle.
Ability to understand and willingness to sign a written informed consent document indicating their willingness to have their tissue or biologic fluid specimens used for research as outlined in this protocol.
Patients younger than 18 years of age and older than 2 months with a histologically or cytologically confirmed diagnosis of cancer (solid tumor or hematologic malignancy) who are being treated for cancer at the NIH Clinical Center or participating clinical sites and who will already be undergoing a clinically necessary medical procedure during which tumor tissue will be resected or needle biopsy tissue or bone marrow aspirate collected. Tissue from neonates will not be collected.
Ability and willingness to assent to participation, utilizing an explanation that is understandable/age appropriate, as well as receiving parental permission.
Show More Criteria
11 exclusion criteria prevent from participating
Specimen collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response (CR).
Blood only collections from patients with solid tumors or hematologic malignancy demonstrating partial or stable disease response: * Blood will not be collected from patients whose disease demonstrates ongoing partial response or ongoing stable disease given the poor rate of model generation from such specimens. * Blood will not be collected from patients between doses within a single treatment cycle.
Blood only collections from patients with partial or stable disease response: * Blood will not be collected from patients whose disease demonstrates ongoing partial response or ongoing stable disease given the poor rate of model generation from such specimens. * Blood will not be collected from patients between doses within a single treatment cycle.
Specimen collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response (CR) based on imaging.
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 17 locations

Recruiting

Emory University

Atlanta, United StatesOpen Emory University in Google Maps
Recruiting

Indiana University - Purdue

Indianapolis, United States
Recruiting

University of Iowa

Iowa City, United States
Recruiting

Johns Hopkins University

Baltimore, United States
Recruiting
17 Study Centers